31 May 2016 - Trevicta is the first treatment for schizophrenia to be administered four times a year.

Janssen-Cilag International NV announced today that the European Commission has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients.

Trevicta will provide the longest dosing interval available for an antipsychotic medication in the European Union, allowing patients to maintain an optimal level of treatment in their blood with fewer administrations, compared to currently available antipsychotic treatments. This may improve outcomes for patients, carers and healthcare professionals.

Trevicta is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on Xeplion, a 1-monthly paliperidone palmitate product that was approved in 2011 for the maintenance treatment of schizophrenia in the European Union.

For more details, go to: http://www.businesswire.com/news/home/20160531005632/en/European-Commission-Approves-TREVICTA®-paliperidone-palmitate-3-monthly